Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma

Kristi M Lara; Gino K In; George R Matcuk Jr; Arjun Mehta; James S Hu

doi:10.1016/j.jdcr.2018.10.003

Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma

JAAD Case Rep. 2018 Nov 7;4(10):1004-1006. doi: 10.1016/j.jdcr.2018.10.003. eCollection 2018 Nov.

Authors

Kristi M Lara¹, Gino K In¹, George R Matcuk Jr¹, Arjun Mehta¹, James S Hu¹

Affiliation

¹ University of Southern California, Los Angeles, California.

No abstract available

Keywords: CR, complete response; CT, computed tomography; FDA, US Food and Drug Administration; MCC, Merkel cell carcinoma; Merkel cell carcinoma; PD-1, programmed cell death protein-1; PD-L1, programmed death ligand-1; PR, partial response; TVEC, talimogene laherparepvec; pembrolizumab; programmed cell death-1; programmed death ligand-1; talimogene laherparepvec.

Publication types

Case Reports